A citation-based method for searching scientific literature

Ayse Mavi, Muammer Urhan, Jian Q Yu, Hongming Zhuang, Mohamed Houseni, Tevfik F Cermik, Dhurairaj Thiruvenkatasamy, Brian Czerniecki, Mitchell Schnall, Abass Alavi. J Nucl Med 2006
Times Cited: 121







List of co-cited articles
587 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Rakesh Kumar, Vilert A Loving, Anil Chauhan, Hongming Zhuang, Schnall Mitchell, Abass Alavi. J Nucl Med 2005
160
40

Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
H Zhuang, M Pourdehnad, E S Lambright, A J Yamamoto, M Lanuti, P Li, P D Mozley, M D Rossman, S M Albelda, A Alavi. J Nucl Med 2001
470
39


Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.
Alexander Matthies, Marc Hickeson, Andrew Cuchiara, Abass Alavi. J Nucl Med 2002
270
35

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
N Avril, C A Rosé, M Schelling, J Dose, W Kuhn, S Bense, W Weber, S Ziegler, H Graeff, M Schwaiger. J Clin Oncol 2000
348
21

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Andreas Buck, Holger Schirrmeister, Thorsten Kühn, Changxian Shen, Thomas Kalker, Jörg Kotzerke, Anja Dankerl, Gerhard Glatting, Sven Reske, Torsten Mattfeldt. Eur J Nucl Med Mol Imaging 2002
207
20

The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?
L M Hamberg, G J Hunter, N M Alpert, N C Choi, J W Babich, A J Fischman. J Nucl Med 1994
332
19


Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
A A Zytoon, K Murakami, M R El-Kholy, E El-Shorbagy. Clin Radiol 2008
41
41

Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Yoshihiro Nishiyama, Yuka Yamamoto, Kotaro Fukunaga, Naruhide Kimura, Akihiro Miki, Yasuhiro Sasakawa, Hisao Wakabayashi, Katashi Satoh, Motoomi Ohkawa. J Nucl Med 2006
90
17

Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity.
Yan Xiu, Chirdeep Bhutani, Thiruvenkatasamy Dhurairaj, Jian Q Yu, Simin Dadparvar, Swapna Reddy, Rakesh Kumar, Hua Yang, Abass Alavi, Hongming Zhuang. Clin Nucl Med 2007
100
16

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer.
A R Boerner, M Weckesser, H Herzog, T Schmitz, W Audretsch, U Nitz, H G Bender, H W Mueller-Gaertner. Eur J Nucl Med 1999
107
15

A PET study of 18FDG uptake in soft tissue masses.
M A Lodge, J D Lucas, P K Marsden, B F Cronin, M J O'Doherty, M A Smith. Eur J Nucl Med 1999
210
15

18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Yoshiki Demura, Tatsuro Tsuchida, Takeshi Ishizaki, Shiro Mizuno, Yoshitaka Totani, Shingo Ameshima, Isamu Miyamori, Masato Sasaki, Yoshiharu Yonekura. J Nucl Med 2003
154
15

Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients.
Shih-Ya Ma, Lai-Chu See, Chyong-Huey Lai, Hung-Hsueh Chou, Chien-Sheng Tsai, Koon-Kwan Ng, Swei Hsueh, Wuu-Jyh Lin, Jenn-Tzong Chen, Tzu-Chen Yen. J Nucl Med 2003
81
17

Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Y Nakamoto, T Higashi, H Sakahara, N Tamaki, M Kogire, R Doi, R Hosotani, M Imamura, J Konishi. Cancer 2000
162
14

Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.
F Crippa, E Seregni, R Agresti, C Chiesa, C Pascali, A Bogni, D Decise, V De Sanctis, M Greco, M G Daidone,[...]. Eur J Nucl Med 1998
134
14

Advantage of delayed whole-body FDG-PET imaging for tumour detection.
K Kubota, M Itoh, K Ozaki, S Ono, M Tashiro, K Yamaguchi, T Akaizawa, K Yamada, H Fukuda. Eur J Nucl Med 2001
186
14

Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules.
Khaled Alkhawaldeh, Gonca Bural, Rakesh Kumar, Abass Alavi. Eur J Nucl Med Mol Imaging 2008
88
15

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
N Avril, M Menzel, J Dose, M Schelling, W Weber, F Jänicke, W Nathrath, M Schwaiger. J Nucl Med 2001
298
14

Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Rong Tian, Minggang Su, Ye Tian, Fanglan Li, Lin Li, Anren Kuang, Jiancheng Zeng. Skeletal Radiol 2009
68
20

Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Ashraf Anas Zytoon, Koji Murakami, Mohamed Ramdan El-Kholy, Emad El-Shorbagy, Osama Ebied. Eur J Radiol 2009
25
56

Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
M G Caprio, A Cangiano, M Imbriaco, F Soscia, G Di Martino, A Farina, G Avitabile, L Pace, P Forestieri, M Salvatore. Radiol Med 2010
29
48

Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.
Jeong Won Lee, Seok-Ki Kim, Sang Mi Lee, Seung Hwan Moon, Tae-Sung Kim. Mol Imaging Biol 2011
56
25

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
Ayse Mavi, Tevfik F Cermik, Muammer Urhan, Halis Puskulcu, Sandip Basu, Jian Q Yu, Hongming Zhuang, Brian Czerniecki, Abass Alavi. J Nucl Med 2007
62
20

High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.
Wendie A Berg, Irving N Weinberg, Deepa Narayanan, Mary E Lobrano, Eric Ross, Laura Amodei, Lorraine Tafra, Lee P Adler, Joseph Uddo, William Stein,[...]. Breast J 2006
139
13

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Shigeto Ueda, Hitoshi Tsuda, Hideki Asakawa, Takashi Shigekawa, Kazuhiko Fukatsu, Nobuo Kondo, Mikio Yamamoto, Yukihiro Hama, Katsumi Tamura, Jiro Ishida,[...]. Jpn J Clin Oncol 2008
151
13

Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
Tatsuya Higashi, Tsuneo Saga, Yuji Nakamoto, Takayoshi Ishimori, Marcelo H Mamede, Michihiko Wada, Ryuichiro Doi, Ryo Hosotani, Masayuki Imamura, Junji Konishi. J Nucl Med 2002
165
12

The relationship between FDG uptake in PET scans and biological behavior in breast cancer.
Wataru Shimoda, Mitsuhiro Hayashi, Koji Murakami, Tetsunari Oyama, Masakatsu Sunagawa. Breast Cancer 2007
71
16

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.
David Groheux, Sylvie Giacchetti, Jean-Luc Moretti, Raphael Porcher, Marc Espié, Jacqueline Lehmann-Che, Anne de Roquancourt, Anne-Sophie Hamy, Caroline Cuvier, Laetitia Vercellino,[...]. Eur J Nucl Med Mol Imaging 2011
235
12

When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
Gang Cheng, Drew A Torigian, Hongming Zhuang, Abass Alavi. Eur J Nucl Med Mol Imaging 2013
104
12




Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
A Gil-Rendo, F Martínez-Regueira, G Zornoza, M J García-Velloso, C Beorlegui, N Rodriguez-Spiteri. Br J Surg 2009
111
10

SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
Sylvain Beaulieu, Paul Kinahan, Jeffrey Tseng, Lisa K Dunnwald, Erin K Schubert, Pam Pham, Barbara Lewellen, David A Mankoff. J Nucl Med 2003
94
9

Evolving role of positron emission tomography in breast cancer imaging.
William B Eubank, David A Mankoff. Semin Nucl Med 2005
103
9

Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Massimo Imbriaco, Maria Grazia Caprio, Gennaro Limite, Leonardo Pace, Teresa De Falco, Ermanno Capuano, Marco Salvatore. AJR Am J Roentgenol 2008
29
31

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.
Rakesh Kumar, Anil Chauhan, Hongming Zhuang, Prem Chandra, Mitchell Schnall, Abass Alavi. Breast Cancer Res Treat 2006
128
9

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.
Reinhard Bos, Jacobus J M van Der Hoeven, Elsken van Der Wall, Petra van Der Groep, Paul J van Diest, Emile F I Comans, Urvi Joshi, Gregg L Semenza, Otto S Hoekstra, Adriaan A Lammertsma,[...]. J Clin Oncol 2002
403
9

Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions.
Eric Laffon, Henri de Clermont, Hugues Begueret, Jean-Marc Vernejoux, Matthieu Thumerel, Roger Marthan, Dominique Ducassou. Nucl Med Commun 2009
38
23

Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity.
Francis J Cloran, Kevin P Banks, Won S Song, Young Kim, Yong C Bradley. Lung Cancer 2010
47
19

Performance of FDG PET/CT in the clinical management of breast cancer.
David Groheux, Marc Espié, Sylvie Giacchetti, Elif Hindié. Radiology 2013
139
9

18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
Alexander M Spence, Mark Muzi, David A Mankoff, S Finbarr O'Sullivan, Jeanne M Link, Thomas K Lewellen, Barbara Lewellen, Pam Pham, Satoshi Minoshima, Kristin Swanson,[...]. J Nucl Med 2004
114
8


Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
H Schirrmeister, T Kühn, A Guhlmann, C Santjohanser, T Hörster, K Nüssle, K Koretz, G Glatting, A Rieber, R Kreienberg,[...]. Eur J Nucl Med 2001
167
8

FDG PET, PET/CT, and breast cancer imaging.
Eric L Rosen, William B Eubank, David A Mankoff. Radiographics 2007
139
8

Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
F Crippa, R Agresti, E Seregni, M Greco, C Pascali, A Bogni, C Chiesa, V De Sanctis, V Delledonne, B Salvadori,[...]. J Nucl Med 1998
126
8

Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
F Dehdashti, J E Mortimer, B A Siegel, L K Griffeth, T J Bonasera, M J Fusselman, D D Detert, P D Cutler, J A Katzenellenbogen, M J Welch. J Nucl Med 1995
248
8

Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
Tomoo Inoue, Kenji Yutani, Tetsuya Taguchi, Yasuhiro Tamaki, Eiichi Shiba, Shinzaburo Noguchi. J Cancer Res Clin Oncol 2004
72
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.